VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, is presenting two abstracts with new data on its first product, the Nu.Q? Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, October 15 through Saturday, October 17. 

"The data demonstrate that the Nu.Q? Vet Cancer Screening Test has a high sensitivity and specificity in relation to both Lymphoma and Hemangiosarcoma detection in a large and varied cohort," said Heather Wilson-Robles, Professor at Texas A&M University, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC, and President-Elect of the VCS. "The results show an Area Under the Curve (AUC) of 87.3% and 97.6%, respectively, for Lymphoma and Hemangiosarcoma.

Dr. Robles added, "These positive findings provide us with real confidence as we move forward towards the launch of our first product, the Nu.Q? Vet Cancer Screening Test, anticipated in the coming weeks. Early diagnosis has a huge potential to help improve the treatment and the quality of life for dogs as well as providing valuable additional information to inform the clinical decision-making process."

An interview with Heather Wilson-Robles, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC.

Cancer is the most common cause of death in dogs over the age of two years old in the U.S. and up to 50% of all dogs over the age of 10 develop cancer in their lifetime. Together, Lymphoma and Hemangiosarcoma make up approximately one third of canine cancers. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal. The Nu.Q? Vet Cancer Screening Test is a low-cost, easy to use ELISA-based screening test that measures and identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample to enable a streamlined and less invasive diagnostic process.

The studies were carried out at Texas A&M University on 334 samples (Healthy Control n=134, Lymphoma n=127, Hemangiosarcoma n=73) which included a variety of breeds, genders, weights, ages and different cancer stages.